Emerging Trends in Ophthalmic Drug Delivery: Focus on NSAIDs and Corticosteroids. (PubMed, Drug Metab Bioanal) - Oct 15, 2026 - "Of particular interest, prodrug medications, such as nepafenac, are metabolized intraocularly and provide greater inhibition of cyclooxygenase-2 (COX-2)...Immunopharmacology, by the design of immunosuppressive drugs such as cyclosporine A, is also another branch of anti-inflammatory therapies, such as for chronic ocular surface diseases, such as dry eye. Nano-based and combination corticosteroids have been effective methods for controlled inflammation and synergy. Together with nanotechnology and the incorporation of biopharmaceutical screening, the era is opening to a new generation of ophthalmic anti-inflammatory therapy with lower risk, greater efficacy, and a patient-centered approach."
Journal • Dry Eye Disease • Inflammation • Keratitis • Ocular Inflammation • Ophthalmology • Uveitis
|
|
Dushyant; Ashwani K Dhingra; Gurvirender Singh; Manish Kumar; Navneet Mehan; Sheetal Devi; Smita Narwal; Vipin Saini
|